Markets open

Royalty Pharma plc Class A Ordinary Shares

RPRX · Nasdaq

Analyst Consensus

Buy

7 analysts

$58

Current

—

Low

$62

Average

—

High

Average target implies +6.82% versus the current price.

The ratings synthesis for RPRX has not been generated yet.

Rating Actions

No individual rating actions have been captured for RPRXyet. Consensus figures above come from Nasdaq's aggregate feed.

Rating actions are extracted from published reporting. Each row links to its source.

Covering Firms

B OF A GLBL RES

GOLDMAN SACHS

JP MORGAN SECUR

MORGAN STANLEY

TD COWEN

TIGRESS FINANCI

UBS

Symbol: RPRX
Type: Stock
Sector: Health Care
Industry: Biotechnology: Pharmaceutical Preparations
Country: North America
Exchange: Nasdaq

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry's leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators.

Analyst Consensus

See all

Buy

7 analysts

$58

Current

—

Low

$62

Average

—

High

Average target implies +6.82% versus the current price.

Earnings History

BeatMissNo estimate

Royalty Pharma plc Class A Ordinary Shares

Analyst Consensus

Rating Actions

Covering Firms

Peers